Oncology Central

AACR 2018: Positive data announced for KEYTRUDA® in adjuvant melanoma

Merck (NJ, USA) (known as MSD outside the United States and Canada) and the European Organisation for Research and Treatment of Cancer (EORTC) have announced findings from their Phase III KEYNOTE-054 trial.

In this trial, KEYTRUDA® (pembrolizumab) significantly prolonged recurrence-free survival (RFS), reducing the risk of disease recurrence by 43% compared with placebo as an adjuvant therapy in resected, high-risk stage III melanoma patients.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.